Small molecule · developed by Rising
Sufentanil is an intravenous and sublingual formulation studied for acute moderate-to-severe pain, including postoperative pain after major upper or lower abdominal surgery.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02662556 | Phase 3 | Acute Moderate-to-severe Pain | Completed | TLPH |
| NCT02447848 | Phase 3 | Moderate-to-severe Acute Pain | Completed | TLPH |
| NCT02356588 | Phase 3 | Post-Operative Pain | Completed | TLPH |
| NCT00718081 | Phase 2 | Major Upper or Lower Abdominal Surgery | Completed | TLPH |
| NCT01639729 | Phase 1 | Pharmacokinetics | Completed | TLPH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Moderate-to-severe PainMajor Upper or Lower Abdominal SurgeryModerate-to-severe Acute PainPharmacokineticsPost-Operative Pain